The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
ORGANIZATION
Pharma FTC Revises Food and Drink Rules for Doctors for 1st Time in 10-Plus Years
The Fair Trade Council of the Ethical Pharmaceutical Drugs Marketing Industry has revised its rules on the provisioning of food and beverages by pharmaceutical companies to doctors for the first time in over 10 years. Its aim is to give…
To read the full story
ORGANIZATION
- Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
- Hata Comes Back to Helm FIRM after 2 Years
June 10, 2025
- Pharma FTC Revises Food and Drink Rules for Doctors for 1st Time in 10-Plus Years
June 5, 2025
- New FPMAJ Chair Pushes Category-Based Drug Pricing to Ensure Innovation, Stable Supply
June 5, 2025
- New JPMA Chief Calls for Clear-Cut Evaluation of Innovation in FY2026 Reform
June 3, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…